[go: up one dir, main page]

WO2007055629A1 - Optimisation de la liberation d'une poudre medicamenteuse seche - Google Patents

Optimisation de la liberation d'une poudre medicamenteuse seche Download PDF

Info

Publication number
WO2007055629A1
WO2007055629A1 PCT/SE2005/001828 SE2005001828W WO2007055629A1 WO 2007055629 A1 WO2007055629 A1 WO 2007055629A1 SE 2005001828 W SE2005001828 W SE 2005001828W WO 2007055629 A1 WO2007055629 A1 WO 2007055629A1
Authority
WO
WIPO (PCT)
Prior art keywords
dose
substrate member
air
suction tube
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2005/001828
Other languages
English (en)
Inventor
Mattias Myrman
Mats Eriksson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mederio AG
Original Assignee
Mederio AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mederio AG filed Critical Mederio AG
Publication of WO2007055629A1 publication Critical patent/WO2007055629A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Definitions

  • the present invention relates to a method for releasing and dispersing into a stream of air a metered dose of dry medication powder from a substrate member, and more specifically to a method of optimizing release of a metered dry powder dose from a substrate member and entraining the powder into an inhalation airflow.
  • MDIs metered dose inhalers
  • DPIs dry powder inhalers
  • MDIs use medicaments in liquid form and may use a pressurized drive gas to release a dose.
  • Nebulizers are fairly big, non-portable devices.
  • Dry powder inhalers have become more and more accepted in the medical service, because they deliver an effective dose in a single inhalation, they are reliable, often quite small in size and easy to operate for a user.
  • Two types are common, multi-dose dry powder inhalers and single dose dry powder inhalers.
  • Multi-dose devices have the advantage that a quantity of medicament powder, enough for a large number of doses, is stored inside the inhaler and a dose is metered from the store shortly before it is supposed to be inhaled.
  • Single dose inhalers either require reloading after each administration or they may be loaded with a limited number of individually packaged doses, where each package is opened shortly before inhalation of the enclosed dose is supposed to take place.
  • Single dose dry powder inhalers capable of pulmonary delivery of pre-metered, systemically acting and sensitive medicaments are attracting much interest today, especially when such devices provide protection for formulations against varying ambient conditions, in particular humidity.
  • the active substance in dry powder form suitable for inhalation needs to be finely divided so that the majority by mass of particles in the powder is between 1 and 5 ⁇ m in aerodynamic diameter (AD). Powder particles larger than 5 ⁇ m in AD tend not to deposit in the lung when inhaled but to stick in the mouth and upper airways, where they are medicinally wasted and may even cause adverse side effects.
  • finely divided powders, suitable for inhalation are rarely free flowing but tend to stick to all surfaces they come in contact with and the small particles tend to aggregate into lumps. This is due to van der Waal forces generally being stronger than the force of gravity acting on small particles having diameters of 10 ⁇ m or less.
  • micronization technologies known in the art.
  • a common practice in the pharmaceutical industry is to dilute the active substance further, in order to increase the nominal dose mass to a level, which the filling method of choice can handle.
  • volumetric doses in prior art have masses in a range from 5 to 50 mg.
  • the drug formulation there are a number of well-known techniques, as mentioned above, to obtain an appropriate primary particle size distribution to ensure correct lung deposition for a high percentage of the dose.
  • modifying the forces between the particles and thereby obtaining a powder with e.g. small adhesive forces Such methods include modification of the shape and surface properties of the particles, e.g.
  • porous particles and controlled forming of powder pellets as well as addition of an inert carrier with a larger average particle size (so called ordered mixture).
  • an inert carrier with a larger average particle size so called ordered mixture.
  • a narrow particle size distribution providing a high fine particle fraction (FPF) of the active pharmaceutical ingredient (API) formulation is an advantage, where the mass median aerodynamic diameter (MMAD) preferably is in a range between 0.5 and 3 ⁇ m, if pulmonary delivery is the objective.
  • MMAD mass median aerodynamic diameter
  • Novel drugs both for local and systemic delivery, often include biological macromolecules, which put completely new demands on the formulation.
  • WO 02/ 11803 US 6,696,090
  • a method and a process is disclosed of preparing a so called electro-powder, suitable for forming doses by an electro-dynamic method.
  • the disclosure stresses the importance of controlling the electrical properties of a medication powder and points to the problem of moisture in the powder and the need of low relative humidity in the atmosphere during dose forming.
  • a successful delivery to the deep lung also assumes that the inspiration takes place in a calm manner to decrease air speed in the airways and thereby reduce deposition by impaction in the upper respiratory tracts.
  • the advantages of using the inhalation power of the user to full potential in a prolonged, continuous dose delivery interval within the inhalation cycle is disclosed in our US Patent No. 6,622,723 (WO 01/34233 Al), which is incorporated herein by reference.
  • the patent presents several devices for efficient distribution of pharmaceutical compositions in fine powder form in the inspiration air, without needing other sources of energy than the power of the airstream resulting from the user's inhalation.
  • the preferred embodiments of the disclosures were based primarily on an electro-dynamic method of producing pre-metered doses of finely divided APIs with or without excipients present in a mixture. Most of the doses were porous, which is easily obtained in the electro-dynamic forming method, and
  • the present invention is directed to improving the Air-razor method and to disclose some preferred embodiments of a device performing the improved method.
  • a method for releasing and dispersing into flowing air a dose of dry medication powder and more specifically a method of optimizing emission of the dose from a dry powder inhaler comprising an Air-razor device for releasing powder.
  • the present invention does not require other sources of energy besides the power of the inhalation effort by the receiver to produce a very high degree of dose release from a substrate member and efficient dispersal of the dose into streaming air.
  • FIG. 1 illustrates the different forces acting on a stationary particle situated in a stream of air
  • FIG. 2 illustrates in a timing diagram a typical inhalation cycle showing pressure and flow
  • FIG. 3 illustrates test data from in-vitro testing of an optimized Air- razor device in an adapted DPI
  • FIG. 4 illustrates in a stylized drawing a substrate member and a concentrated dose thereon
  • FIG. 5 illustrates in a stylized drawing a substrate member and a spread-out dose thereon
  • FIG. 6 illustrates in a stylized drawing a substrate member and a dose in a spot thereon
  • FIG. 7 illustrates in perspective (Fig. Ia), top (Fig. Ib) and side (Fig. Ic) views a particular embodiment of a sealed dose container filled with a dose of a medicament and a dose of an excipient;
  • FIG. 8 illustrates a sealed dose container after agitation filled with a dose of a medicament consisting of two deposits and a dose of an excipient consisting of three deposits where the doses have become partly mixed;
  • the present invention makes the Air-razor method and device applicable to all types of dry powder formulations of inhalable medication powders. Furthermore, standard filling methods and equipment may be used to meter and fill doses of a chosen formulation. The doses can then be applied to an adapted DPI, comprising an Air-razor device optimized for the formulation, where the emitted doses and the fine particle doses (FPD) delivered by the DPI present excellent results in terms of quantity and quality compared to the original, metered doses of said chosen formulation. Naturally, the emitted dose and the FPD cannot exceed what is in the metered dose before it is sucked up.
  • Air-razor method refers to a method where the difference in external forces acting on two particles in a dose overcomes the adhesion and friction forces holding them together.
  • Air-razor device referds to a device capable of providing, via energy imput by a user via inhalation and movement of a dose and/ or suction tube, a difference in external forces acting on two particles that overcomes the adhesion and friction forces holding them together. The external forces referred to ensue from the induced flow of air developing from a suction effort provided by a user and applied to an adapted DPI comprising an Air- razor device.
  • the present invention discloses an improved Air-razor method of releasing a dose of dry medication powder from a substrate member and dispersing the powder particles into an airstream.
  • a dose of dry medication powder may be emitted from a dry powder inhaler comprising an Air-razor device, whereby the dose is delivered to a receiver with an extremely high fine particle dose (FPD) of the emitted dose coming very close to the original fine particle fraction (FPF) of the original powder formulation.
  • FPD extremely high fine particle dose
  • FPF fine particle fraction
  • the invention teaches that the Air-razor method may be optimized and the method implemented in an Air-razor device design, which offers very low retention of particles both on the substrate member, including associated surfaces, and downstream flow channels, which are in contact with the powder before and during dose emission.
  • Test data show excellent results in emitted dose relative metered dose and in delivered fine particle dose relative emitted dose, when the Air-razor is optimized for a particular powder formulation. See Figure 3, which illustrates in-vitro testing of an optimized Air-razor method and an Air-razor device applied in a dry powder inhaler device.
  • the total dose is 1 mg of a pure, micronized API.
  • the total dose in the example is equivalent to a metered dose.
  • the tests show that the FPD ⁇ 3.5 ⁇ m of the delivered dose (equivalent to emitted dose) is more than 70 % for 4 kPa suction pressure and more than 65 % for 2 kPa suction pressure. However, our tests also show that although Air-razor performance drops off below 2 kPa, the drop is not dramatic but slow with decreasing pressure. Pressures above 4 kPa, on the other hand, improve performance slightly, but few users are capable of producing pressures much higher than 4 kPa.
  • the optimized Air-razor is quite insensitive to variations in the time period for a relative motion of substrate member and a suction tube, as illustrated in Figure 3 ('standard inhalation time' signifies motion in approximately 0.7 s, 'fast inhalation time' signifies about 0.3 s for the motion and 'slow inhalation time' signifies about 1.2 s for the relative motion to be completed). However, it is worth pointing out that longer inhalation times may be used without any detrimental effects on performance up to about 6 s, which is approximately the maximum time span for a user's suction capability.
  • the Air-razor is also insensitive to the orientation of the inhaler, i.e. the Air-razor itself.
  • particle retention on the substrate member acting as carrier of the dose is also minimized by the optimization, which may optionally also include minimizing retention on the inside walls of the downstream air channels.
  • Total retention is normally less than 10 % as illustrated in Figure 3.
  • suitable powder formulations include those produced by jet-milling, spray-drying and super-critical crystallization. Powders of micronized, solid particles or powders of porous particles of low density can be advantageously released and aerosolized by the Air-razor method.
  • suction tube inlet aperture size which shall preferably have a slightly larger diameter at right angles to the direction of the motion than the width of the dose deposit(s), a gap between the inlet aperture and the substrate member of preferably not more than two millimetres and a speed of the relative motion between substrate member and suction tube, or vice versa, preferably not exceeding 100 mm/s.
  • time for the relative motion within the time for a suction effort, e.g. an inhalation cycle, is in a range of approximately 0.2 s to 2 s from beginning to end for optimal results.
  • An important element of the Air-razor method is a relative motion between a a suction tube, comprising an inlet nozzle, and a powder dose.
  • the term "relative motion” refers to the non-airborne powder, which constitutes a dose that is gradually moved, relatively speaking, by the motion into close proximity to the inlet aperture of said suction tube.
  • a motion of the dose is preferably brought about by moving a • substrate onto which the dose is deposited, but other means e.g. vibrating or shock devices may also be used.
  • the mentioning of "motion" or “moving” in relation to “powder” or “powder dose” or “dose” refers to the dose, preferably loaded on a substrate member, before the powder particles are released and dispersed into air.
  • the dose comprises at least one powder deposit, e.g. in a single, concentrated spot or in a series of such spots, or a deposit or deposits spread out onto an area of the substrate member.
  • the pattern of how a dose is arranged onto the substrate member depends mainly on the selected method of dose filling, e.g. gravimetric, volumetric, electrostatic and electro-dynamic methods may be used, including combibnations thereof.
  • the relative motion between powder dose and suction tube preferably begins, either automatically by breath- actuation or by manual control, when a predefined, minimum airflow has already been established through the suction tube.
  • the minimum airflow develops when a pre-defined, minimum suction power is applied to the suction tube, said suction power selected to secure enough Air-razor power to release the powder of the dose.
  • the timing of the motion must be adapted to the style and size of the substrate member and the volume and mass of the dose. We have found that an optimum time for the motion to be completed is between 0.2 and 2 seconds, but the performance of the Air-razor device is not necessarily less at shorter motion intervals than 0.2 seconds or longer intervals than 2 seconds.
  • the dose volume and dose mass must be considered when optimizing the Air-razor performance.
  • compact, volumetrically metered doses in a range from below 1 mg to more than 10 mg may be very efficiently released by the Air-razor device in approximately 1 second.
  • Such doses may be concentrated to a particular spot on a substrate or the powder may be distributed, e.g. by shaking, over the whole substrate area without any difference in Air-razor performance. So, within the indicated time frame of 0.2 to 2 seconds almost any dose is released and delivered to a user with excellent results in emitted dose and FPD.
  • a satisfactory Air-razor effect is normally generated by a suction between 2 and 4 kPa, which gives rise to an airflow in a range from 20 1/min to 60
  • FIG. 2 which illustrates a timing diagram of an inhalation period 1' and a suction pressure curve 'P' and the following airflow 'Q' as a result.
  • Figures 4, 5 and 6 illustrate top and side views, of different embodiments of single deposits of doses 22 on a target area 35 of a substrate member 34.
  • doses may be very concentrated in a spot, or spread out over most of the available area.
  • the Air-razor is preferably optimized with regard for the type of dose, including type of formulation, that is going to be loaded into an inhaler where the Air-razor is applied.
  • a so-called pod pattern pending
  • a sealed dose container is to be preferred in an application where the present invention is to be put to use. See our Application US 11/ 154677, which is hereby included in this document by reference.
  • a pod container may, if necessary, be made as a high barrier seal container offering a very high level of moisture protection and which is in itself dry, i.e. it does not contain water.
  • Figure 7 illustrating a pod carrying a sealed container in a perspective drawing.
  • Figure 7a shows a sealed container 33 (seal 31) put into a protective casing 41 adapted for insertion into a dry powder inhaler.
  • Figure 7b shows a top view of the carrier/ container and indicates a dose of a dry powder medicament 22 and a dose of a dry powder excipient consisting of two depositions 21 inside the container 33 under, a seal 31.
  • Figure 7c illustrates a side view of the carrier/ container shown in Figure Ib.
  • Figure 8 illustrates a similar container to Figure 7, but the medicament dose consists of two deposits 22 and the excipient dose consists of deposit 21 after agitation of the container, whereby the deposits 21 and 22 have become partly mixed in a load 23.
  • the medication powder comprises one or more pharmacologically active substances and optionally one or more excipients.
  • the terms “powder” or “medication powder” are used to signify the substance in the form of dry powder, which is the subject of release from a substrate member and dispersal into an airstream by the disclosed invention and intended for deposition at a selected target area of a receiver's airways.
  • Particles adjacent to other particles or to a substrate member will adhere to each other.
  • Many different types of adhesive forces will play roles in the total adhesive force between a particle and the environment, whether that is another particle, an aggregate of particles, a substrate member or a combination thereof.
  • the types of adhesive forces acting on a particle can be van der Waal forces, capillary forces, electrical forces, electrostatic forces, etc.
  • the relative strengths and ranges of these forces vary with e.g. material, environment, size and shape of the particle. The sum of all these forces acting on a particle is hereinafter referred to as an adhesive force.
  • Figure 1 illustrates forces acting on a particle.
  • the force caused by airflow 303 acting on a particle 101 can be divided into two parts, drag force 305 acting parallel to the airflow, and lift force 304 acting perpendicular to the airflow.
  • the condition for freeing the particle is in the static case that lift and drag forces exceed adhesion 301 and friction 302 forces.
  • the efficiency of the Air-razor method may be optimized by careful design of the geometry of involved flow elements with the aim to reach as high a velocity as possible in the releasing area around the suction tube inlet aperture, i.e. where the dose is to be found, but at the same time a smooth transportation of air in other areas. This will minimise the dissipative losses where not wanted and so preserve energy for use in the area adjacent to and into the powder deposit(s).
  • suction is applied to the suction tube outlet, a low-pressure develops that accelerates the air through the suction tube inlet aperture during a short period before a steady state condition is reached. Initially, during the start-up period as the air picks up inertia, the velocity is not high enough to generate the necessary shear forces.
  • the air flow is allowed to build up before the powder dose is brought adjacent to the suction tube. This ensures that the conditions for an efficient release of the powder exist before the dose deposit(s) is (are) attacked by the air stream.
  • the Air-razor invention makes use of the concentrated flow close to the inside wall of the suction tube inlet nozzle as well as the surfaces of the substrate member, and especially the small gap between the aperture wall on the suction tube inlet and the substrate member.
  • the relative motion introduced between the suction tube and the load of powder, i.e. the substrate member normally serving as carrier, is instrumental in attaining and maintaining the desired conditions stated for releasing all of a powder dose and not just part of it.
  • the low-pressure created by the suction through the suction tube drives air to flow in the direction of the low-pressure.
  • Building up inertia means accelerating the mass in a system, i.e. the mass of the air itself, hence giving the desired high velocity air flow after the acceleration period.
  • the velocity of the flow increases to a point where the flow resistance makes further increase impossible, unless the level of low-pressure is decreased, i.e. the pressure drop is increased, or the flow resistance is decreased.
  • the area exhibiting the highest shear forces is concentrated close to the wall of the inlet aperture of the suction tube nozzle. This concentrated area must be adapted to the powder deposit or deposits making up the dose and which occupy a small or large percentage of the available dose target area of a substrate member.
  • Different powder formulations may behave very differently when filled as at least one deposit on the substrate member. For instance, formulations comprising very porous particles may have very low bulk density and may also present quite small adhesive forces. They often flow quite easily, even if the average particle size is small, and these powders are therefore easy to use in conventional filling systems. Because of the small adhesive forces between particles and between particles and substrate the deposited powder dose is easily broken up after filling, e.g.
  • the dose of a formulation of porous particles needs an Air-razor device, which is capable of spreading the shear forces over a big volume, but which must not necessarily present very high shear forces, since the individual particles are comparatively easy to release from each other and from the substrate.
  • the Air-razor should be adapted to spreading the available airflow energy over a big volume in this case.
  • the formulation comprises fine, micronized particles from e.g.
  • the powder typically presents high adhesive forces, it does not flow easily, porosity is low, bulk density is high and filling is difficult using prior art methods.
  • the dose deposit or deposits hold together well on the substrate member after filling and the substrate area occupied by the dose is small, perhaps not more than a single deposit in the form of a dot, on a fraction of the available dose target area.
  • individual particles require fairly high levels of supplied energy in order to be released and entrained in the air stream.
  • the requirements on the Air-razor are quite different from the previous example. Shear forces need to be high and more concentrated to ensure that all particles of the dose are subjected to a sufficiently high force to be released and de-aggregated from the cluster of particles they may be part of.
  • a third example is a formulation comprising a majority of large particles, preferably of an excipient substance, in a mixture with small particles, some of which constituting the API to be delivered to the deep lung, for instance.
  • This formulation is called an ordered mixture where the large particles act as carriers of the small particles.
  • the dose deposit or deposits hold together well on the substrate member after filling, but take up much more space than the dose of micronized particles in the preceding example.
  • the deposits are not difficult to break up in random clusters of particles by providing energy e.g. vibration.
  • the Air-razor needs to cover the available dose target area and at the same time providing fairly high shear forces over a rather big volume in order to release all particles of the mixture.
  • Optimizing the Air-razor for a dose of a particular powder formulation involves a set of Air-razor parameters, including suction tube inlet aperture size, shape, aperture distance and angle to the substrate, duration of suction and speed and time of relative motion.
  • the relative motion between the suction tube and the dose will let the relatively small and concentrated area of high shear stress traverse over the area occupied by the dose.
  • the velocity of the airflow will not be affected by the motion of the suction tube in relation to the powder dose, because the speed of the relative motion is very much lower than the velocity of the air flow going into the suction tube inlet.
  • the motion of the suction tube forcibly shifts the position of the driving low-pressure relative the contour of the dose in the direction of the motion.
  • the area of high shear forces moves along a path, controlled by the relative motion of the suction tube, such that the high shear forces gradually disperse powder particles into air.
  • the path begins just outside a point of contact between the high shear force area of flowing air and the deposit(s) of the powder dose and passes the dose deposits, if more than one, from the beginning until the end on the substrate member.
  • the dose is deposited by a gravimetric, volumetric or electric method onto a substrate member of a pod container. At least a pre-defined, minimum suction is applied to an outlet of a suction tube also comprising a dose-adapted inlet aperture, thereby starting up at least a minimum airflow into the suction tube inlet e.g. from ambient air.
  • the pod and thereby the dose therein are then moved past the inlet aperture at close proximity in an interval of preferably 0.2 to 2 seconds.
  • the dose is hereby gradually released and entrained into the airflow going through the suction tube.
  • the suction tube inlet aperture is moved at close range past the dose in the pod container, thus releasing the dose by using the Air-razor effect in analogy with the above example.
  • the suction tube inlet aperture and the dose both move to make the airflow into the inlet aperture release the dose gradually by using the Air-razor effect in analogy with the above examples.
  • an Air-razor method comprising filling a dose of a selected powder formulation, said dose intended for inhalation, onto the substrate member using a chosen method of filling; adapting an inlet aperture of a suction tube to the dose and positioning the aperture adjacent to the substrate member at a first, selected distance from the substrate member and at a second, chosen distance from the dose on the substrate member; applying a pre-defined suction pressure to a mouthpiece in fluid connection with an outlet of said suction tube and introducing a relative motion between the suction tube and the substrate member, or vice versa; maintaining said suction pressure for the duration of said motion from beginning to end, such that the inlet aperture appears to traverse the substrate member, or vice versa, and the dose thereon, whereby the motion and the airstream together constitute an Air-razor effect that releases and disperses the powder dose into the airstream going through the mouthpiece into a
  • an Air-razor device optimized according to claim 13 for releasing a dry powder medication dose from a substrate member and disperse the dose into an airflow
  • the Air-razor device comprises: a suction tube having an inlet aperture adapted to the dose and a larger outlet aperture; said inlet aperture positioned adjacent to the substrate member means of moving the suction tube in relation to the substrate member, or vice versa means of controlling the speed of motion suction tube - substrate member.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé se basant sur un outil à rasoir pneumatique qui permet d'améliorer la libération et la dispersion dans l'air typiquement d'une dose de poudre médicamenteuse. Lorsque de l'air est aspiré par un tube d'aspiration, des particules d'une dose de poudre présentées au tube d'aspiration sont progressivement libérées et dispersées dans un écoulement d'air qui pénètre dans le tube d'aspiration. La libération et la dispersion progressives sont réalisées par un déplacement relatif introduit entre le tube d'aspiration et la dose. L'air à haute vitesse qui pénètre dans le tube d'aspiration par son embouchure crée suffisamment de contraintes de cisaillement et d'inertie lorsque l'air en déplacement vient frapper le point initial de la dose. Cette opération de rasoir pneumatique à poudre créée par les contraintes de cisaillement et l'inertie de l'écoulement d'air est suffisamment puissante pour que les particules de poudre adjacentes à l'embouchure du tube mobile d'aspiration soient libérées et ensuite entraînées dans l'écoulement d'air qui passe dans le tube d'aspiration.
PCT/SE2005/001828 2005-11-08 2005-12-01 Optimisation de la liberation d'une poudre medicamenteuse seche Ceased WO2007055629A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/268,553 2005-11-08
US11/268,553 US20070101991A1 (en) 2005-11-08 2005-11-08 Optimizing release of dry medicament powder

Publications (1)

Publication Number Publication Date
WO2007055629A1 true WO2007055629A1 (fr) 2007-05-18

Family

ID=38002500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2005/001828 Ceased WO2007055629A1 (fr) 2005-11-08 2005-12-01 Optimisation de la liberation d'une poudre medicamenteuse seche

Country Status (2)

Country Link
US (1) US20070101991A1 (fr)
WO (1) WO2007055629A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170986A2 (fr) * 2011-06-10 2012-12-13 Arocha Max Appareil distributeur périodontal régulé et applicateur de doses multiples comportant une valve en demi-lune

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030192539A1 (en) * 2002-04-12 2003-10-16 Mattias Myrman De-aggregating and dispersing dry medicament powder into air
US20030192540A1 (en) * 2002-04-12 2003-10-16 Mattias Myrman Therapeutic dry powder preparation
US20030192538A1 (en) * 2002-04-12 2003-10-16 Mattias Myrman Device constituting a powder air-razor
WO2004110404A1 (fr) * 2003-06-19 2004-12-23 Microdrug Ag Doses combinees de tiotropium et de fluticasone
US20050211244A1 (en) * 2004-03-29 2005-09-29 Mederio Ag Dry powder preparations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1240750B (it) * 1990-04-12 1993-12-17 Chiesi Farma Spa Dispositivo per la somministrazione di sostanze medicamentose in polvere
US6055980A (en) * 1991-05-20 2000-05-02 Dura Pharmaceuticals, Inc. Dry powder inhaler
US5213817A (en) * 1991-12-12 1993-05-25 Mcneil-Ppc, Inc. Apparatus for intermittently applying particulate powder material to a fibrous substrate
FI942196L (fi) * 1994-05-11 1995-11-12 Orion Yhtymae Oy Jauheinhalaattori
SE9404439D0 (sv) * 1994-12-21 1994-12-21 Astra Ab Inhalation device
US6142146A (en) * 1998-06-12 2000-11-07 Microdose Technologies, Inc. Inhalation device
TWI224515B (en) * 2000-06-23 2004-12-01 Norton Healthcare Ltd Pre-metered dose magazine for breath-actuated dry powder inhaler

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030192539A1 (en) * 2002-04-12 2003-10-16 Mattias Myrman De-aggregating and dispersing dry medicament powder into air
US20030192540A1 (en) * 2002-04-12 2003-10-16 Mattias Myrman Therapeutic dry powder preparation
US20030192538A1 (en) * 2002-04-12 2003-10-16 Mattias Myrman Device constituting a powder air-razor
WO2004110404A1 (fr) * 2003-06-19 2004-12-23 Microdrug Ag Doses combinees de tiotropium et de fluticasone
US20050211244A1 (en) * 2004-03-29 2005-09-29 Mederio Ag Dry powder preparations

Also Published As

Publication number Publication date
US20070101991A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
AU2003222538B2 (en) Therapeutic dry powder preparation
AU2003230474B2 (en) De-aggregating and dispersing dry medicament powder into air
EP1328310B1 (fr) Inhalateur a poudre seche
US8962063B2 (en) Methods and systems for dosing and coating inhalation powders onto carrier particles
AU2007224178B2 (en) Dry powder inhaler with aeroelastic dispersion mechanism
AU2003225452B2 (en) A device constituting a powder air-razor
JP2014158978A (ja) 投与効率を向上させるデバイス及び製薬組成
JP2008502417A (ja) ポッドを用いる吸入器
WO2016014153A1 (fr) Nébuliseur de poudre sèche
US20070101991A1 (en) Optimizing release of dry medicament powder
HK1074411B (en) Dry powder inhaler

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05815516

Country of ref document: EP

Kind code of ref document: A1